Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 1;12(7):1266–1275. doi: 10.1158/1535-7163.MCT-12-1231

Figure 6. Effect of Minnelide on miR-142-3p or HSPA1B (HSP70) expression in vivo.

Figure 6

(A) Minnelide (0.42 mg/kg daily for seven days i.p.) induces miR-142-3p expression (as assessed by real-time PCR) in three independent human tumor xenografts grown in vivo. Expression of miR-142-3p was normalized against U6. (B) Minnelide reduces HSPA1B (HSP70) mRNA expression (as assessed by real-time PCR) of these same samples in vivo. Expression of HSPA1B (HSP70) was normalized against 18S. The bars represent mean ± SEM, n=3, *p<0.05 (t test).